YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD <li /> Approval triggers ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

U.S. exchange operators are in talks with the Securities and Exchanges Commission on easing regulatory burdens for public ...

I was scrolling through TikTok one evening and stumbled on a video promoting an herbal product that claimed to “prevent pregnancy naturally,” even going as far as saying, “you won’t get pregnant even ...

The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced an updated timeline for submitting its Biologics ...

Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway ...

In this Prominent People in Packaging interview, Aladin Alkhawam discusses the challenges and intricacies of implementing the ...

Enhance your pharmacovigilance operations with our comprehensive training course tailored for pharmaceutical and biologic companies. Gain insights into US, EU, and UK drug safety regulatory ...